Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking

Yuyan Jin, Bruce G. Pollock, Kim Coley, Del Miller, Stephen R. Marder, Jeff Florian, Lon Schneider, Jeffrey Lieberman, Margaret Kirshner, Robert Bies

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8 to 32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One- and 2-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness-of-fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A 1-compartment linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18 200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48% higher in nonsmoking African Americans than in nonsmoking other races (512 L/h vs 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalJournal of Clinical Pharmacology
Volume50
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Perphenazine
Antipsychotic Agents
Schizophrenia
Pharmacokinetics
Smoking
Clinical Trials
Population
African Americans
Population Characteristics
Patient Selection
Linear Models
Weights and Measures

Keywords

  • Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE)
  • Perphenazine
  • Population pharmacokinetics
  • Race and smoke
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE : Impact of race and smoking. / Jin, Yuyan; Pollock, Bruce G.; Coley, Kim; Miller, Del; Marder, Stephen R.; Florian, Jeff; Schneider, Lon; Lieberman, Jeffrey; Kirshner, Margaret; Bies, Robert.

In: Journal of Clinical Pharmacology, Vol. 50, No. 1, 01.2010, p. 73-80.

Research output: Contribution to journalArticle

Jin, Y, Pollock, BG, Coley, K, Miller, D, Marder, SR, Florian, J, Schneider, L, Lieberman, J, Kirshner, M & Bies, R 2010, 'Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking', Journal of Clinical Pharmacology, vol. 50, no. 1, pp. 73-80. https://doi.org/10.1177/0091270009343694
Jin, Yuyan ; Pollock, Bruce G. ; Coley, Kim ; Miller, Del ; Marder, Stephen R. ; Florian, Jeff ; Schneider, Lon ; Lieberman, Jeffrey ; Kirshner, Margaret ; Bies, Robert. / Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE : Impact of race and smoking. In: Journal of Clinical Pharmacology. 2010 ; Vol. 50, No. 1. pp. 73-80.
@article{a1419ba15f1241ba8027d81d5bc919ce,
title = "Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking",
abstract = "The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8 to 32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One- and 2-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness-of-fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A 1-compartment linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18 200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48{\%} higher in nonsmoking African Americans than in nonsmoking other races (512 L/h vs 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.",
keywords = "Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE), Perphenazine, Population pharmacokinetics, Race and smoke, Schizophrenia",
author = "Yuyan Jin and Pollock, {Bruce G.} and Kim Coley and Del Miller and Marder, {Stephen R.} and Jeff Florian and Lon Schneider and Jeffrey Lieberman and Margaret Kirshner and Robert Bies",
year = "2010",
month = "1",
doi = "10.1177/0091270009343694",
language = "English",
volume = "50",
pages = "73--80",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE

T2 - Impact of race and smoking

AU - Jin, Yuyan

AU - Pollock, Bruce G.

AU - Coley, Kim

AU - Miller, Del

AU - Marder, Stephen R.

AU - Florian, Jeff

AU - Schneider, Lon

AU - Lieberman, Jeffrey

AU - Kirshner, Margaret

AU - Bies, Robert

PY - 2010/1

Y1 - 2010/1

N2 - The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8 to 32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One- and 2-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness-of-fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A 1-compartment linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18 200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48% higher in nonsmoking African Americans than in nonsmoking other races (512 L/h vs 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.

AB - The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8 to 32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One- and 2-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness-of-fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A 1-compartment linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18 200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48% higher in nonsmoking African Americans than in nonsmoking other races (512 L/h vs 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.

KW - Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE)

KW - Perphenazine

KW - Population pharmacokinetics

KW - Race and smoke

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=72749103708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72749103708&partnerID=8YFLogxK

U2 - 10.1177/0091270009343694

DO - 10.1177/0091270009343694

M3 - Article

C2 - 19843655

AN - SCOPUS:72749103708

VL - 50

SP - 73

EP - 80

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -